Marietta Investment Partners LLC Acquires 3,437 Shares of Eli Lilly and Company (NYSE:LLY)

Marietta Investment Partners LLC increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 73.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,146 shares of the company’s stock after buying an additional 3,437 shares during the quarter. Eli Lilly and Company accounts for about 1.6% of Marietta Investment Partners LLC’s holdings, making the stock its 17th biggest holding. Marietta Investment Partners LLC’s holdings in Eli Lilly and Company were worth $7,375,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Lynx Investment Advisory bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC bought a new position in Eli Lilly and Company in the second quarter valued at about $36,000. Morton Brown Family Wealth LLC raised its position in Eli Lilly and Company by 45.5% in the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock valued at $41,000 after purchasing an additional 15 shares during the last quarter. Core Wealth Advisors Inc. raised its position in Eli Lilly and Company by 188.2% in the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the last quarter. Finally, Unique Wealth Strategies LLC bought a new position in Eli Lilly and Company in the second quarter valued at about $45,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.7 %

NYSE LLY opened at $921.49 on Monday. The business has a 50 day simple moving average of $895.06 and a 200 day simple moving average of $838.73. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The stock has a market capitalization of $875.79 billion, a P/E ratio of 135.71, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, August 8th. The company reported $3.92 EPS for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,441 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $915.02, for a total value of $1,318,543.82. Following the completion of the sale, the insider now owns 97,367,369 shares of the company’s stock, valued at $89,093,089,982.38. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last quarter, insiders sold 425,000 shares of company stock valued at $394,455,351. Company insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

LLY has been the subject of several research reports. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their target price for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Morgan Stanley reiterated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Barclays increased their target price on Eli Lilly and Company from $913.00 to $1,025.00 and gave the company an “overweight” rating in a research report on Wednesday, July 10th. Bank of America increased their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, JPMorgan Chase & Co. increased their price target on Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $977.35.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.